RPG Life Sciences Limited

NSE: RPGLIFE · Pharmaceuticals

—
52W Range₹1,733 – ₹3,128

Snapshot

Unlock RPG Life Sciences Limited's vital signs

Growth · Profitability · Valuation · Strength · Conviction

Company Overview

Business

RPG Life Sciences Limited is an integrated pharmaceutical company that develops, manufactures, and markets branded formulations, generics, and synthetic active pharmaceutical ingredients (APIs). The company operates across diverse therapeutic categories, including nephrology, oncology, and immunosuppressants, serving both domestic and international markets.

Business Model

The company generates revenue through the sale of finished dosage formulations and synthetic APIs, leveraging its manufacturing capabilities to serve various medical specialties. It operates as a subsidiary of Nucleus Life Trust and maintains a broad portfolio of therapeutic products.

Growth Outlook

Growth is driven by the expansion of its branded formulations portfolio and the continued development of synthetic APIs for global markets. The company focuses on high-growth therapeutic areas such as nephrology and rheumatology to sustain its market position.

Key Risks

  • Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and safety regulations from bodies like the CDSCO and international health authorities.
  • Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can impact profit margins.
  • Competitive Pressure. The company faces intense competition from both domestic and multinational pharmaceutical firms in the branded and generic segments.
  • Currency Risk. As an exporter of APIs and formulations, the company is exposed to foreign exchange rate fluctuations.

Start your research today

Unlock AI insights, financials, peers and live data on RPG Life Sciences Limited and 5,000+ companies — free.

Start your research

Peers · Pharmaceuticals

CompanyMkt CapP/E (TTM)EV/EBITDARev Gr YoYEBITDA MgnROEROCE1Y Return
RPG Life Sciences LimitedRPGLIFE
₹4,217 Cr38.0×22.80—23.7%16.2%16.9%+6.1%
Novartis IndiaNOVARTIND
₹4,241 Cr43.4×30.215.4%37.4%12.2%16.7%+97.9%
Jeena Sikho Lifecare LimitedJSLL
₹4,241 Cr17.9×10.99—45.2%50.6%58.2%-54.0%
Zota Health Care LimitedZOTA
₹4,215 Cr-38.7×365.1878.9%1.9%-22.7%-14.6%-19.5%
Gufic Biosciences LimitedGUFICBIO
₹4,178 Cr56.9×26.9816.7%17.0%11.6%16.9%+28.0%
Aarti Drugs LimitedAARTIDRUGS
₹4,142 Cr21.7×14.01—12.6%13.1%14.5%-7.6%

As of Q2 FY27

Financials